Related Experiment Video
Updated: May 16, 2026
06:06
Adjunctive Diode Laser Therapy and Probiotic Lactobacillus Therapy in the Treatment of Periodontitis and Peri-Implant Disease
Published on: May 9, 2022
Periodontal therapy -- an adjuvant for glycemic control
1Department of Periodontics, Tatyasaheb Kore Dental College & Research Centre, New Pargaon, Kolhapur 416137, Maharashtra, India. dr_abhijitg@yahoo.co.in
Diabetes & Metabolic Syndrome
|December 4, 2012
Summary
Periodontal therapy (PT) can improve glycemic control in type 2 diabetes patients. This treatment helps reduce inflammation and manage blood sugar levels, highlighting the importance of oral health for diabetic individuals.
Area of Science:
- Oral Health
- Endocrinology
- Immunology
Background:
- Periodontitis, an oral infection, involves bacterial plaque and host immune response, leading to systemic inflammation.
- Diabetes mellitus is closely linked to the development, progression, and severity of periodontitis.
- Periodontal therapy (PT) aims to resolve disease signs by removing bacterial components.
Purpose of the Study:
- To raise awareness among medical professionals about the bidirectional relationship between diabetes and periodontitis.
- To emphasize the positive impact of periodontal therapy on diabetes management.
Main Methods:
- A PubMed search was conducted for studies on the effects of PT on glycemic control in type 2 diabetes.
- Key search terms included 'Glycemic control', 'Periodontitis', 'Periodontal therapy', and 'Type 2 diabetes mellitus'.
- The review screened studies published between January 1990 and March 2012.
Main Results:
- Periodontal therapy shows potential as an adjunct to conventional diabetes treatment.
- PT can help improve inflammatory biomarker levels and glycemic status in type 2 diabetic patients.
Conclusions:
- Periodontal therapy aids in ameliorating inflammation and improving glycemic control in type 2 diabetes.
- Further research is needed to fully elucidate the benefits of PT in diabetic individuals.
- Periodontal screening is crucial for glycemic maintenance in diabetic patients.
Related Concept Videos
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:17Oral Hypoglycemic Agents: Sulfonylureas
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...